MEMBANGUN INDUSTRI PODP YANG BERDAYA SAING : REFLEKSI GLOBAL DAN RENCANA STRATEGIS INDONESIA

Nisrina Nabila Az Zahra, Vania Anindira Susatia, Indri Widuri Yani, Davin Ezra Alkan Al Faisal, Mas Rahman Roestan, Evi Sylvia Nurrasjid, Angga Prawira Kautsar

Abstrak


Produk obat derivat plasma (PODP) merupakan hasil pengolahan plasma darah manusia yang digunakan untuk mengobati berbagai kondisi medis, seperti gangguan imun, hemofilia, dan penyakit autoimun. Penggunaan PODP semakin meluas seiring berkembangnya teknologi dan meningkatnya kebutuhan terapi berbasis protein plasma. Namun, perkembangan PODP di Indonesia masih menghadapi tantangan besar, mulai dari keterbatasan pasokan plasma berkualitas hingga ketergantungan pada produk impor. Artikel ini menyajikan tinjauan mengenai jenis PODP, proses produksinya, sistem deteksi patogen, serta upaya global dalam menjamin keamanan dan ketersediaan produk. Tinjauan ini didasarkan pada literatur dari basis data ilmiah seperti Embase, PubMed, EBSCO, dan World of Science dengan kata kunci terkait seperti “plasma-derived medicinal products”, “plasma-derived medicinal products”, dan “plasma fractionation”, yang mencakup aspek klinis, produksi, regulasi, dan industri dari PODP. Kajian ini juga menyoroti potensi Indonesia dalam membangun sistem produksi PODP yang mandiri dan berkelanjutan. Melalui pemahaman yang komprehensif, diharapkan artikel ini dapat menjadi referensi bagi pemangku kebijakan dan praktisi kesehatan dalam merumuskan strategi nasional yang tepat. Melalui tinjauan ini, disimpulkan bahwa dengan komitmen kebijakan yang kuat, peningkatan infrastruktur, dan kolaborasi lintas sektor, Indonesia memiliki peluang besar untuk mengembangkan industri PODP yang aman, mandiri, dan berdaya saing global.


Teks Lengkap:

PDF

Referensi


Burnouf, T., Epstein, J., Faber, J.-C., & Smid, W. M. (2023). Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries. Vox Sanguinis, 119(2), 102–109.

Buchacher, A., Iberer, G., & Lafferty, M. (2009). Antibody-based virus neutralization assays – Concepts, limitations and perspectives. Bioorganic & Medicinal Chemistry, 17(10), 3704–3710.

De Angelis, V., & Breda, A. (2013). Plasma-derived medicinal products self-sufficiency from national plasma: to what extent? Blood Transfusion, 11(4), 132–137.

De Silvestro, G., Marson, P., Breda, A., & De Angelis, V. (2019). Plasma-derived industry and plasma-derived medicinal products in the Italian National Blood Transfusion Service. Transfusion and Apheresis Science, 58(5), 102666.

de Narbonne, L. (2010). Le fractionnement et les investissements en recherche clinique concernant les médicaments dérivés du sang (MDS) chez Octapharma. La Revue de Médecine Interne, 31( 2), 6–8.

Farrugia, A., & Scaramuccia, D. (2017). The dynamics of contract plasma fractionation. Biologicals, 46, 159–167.

Farcet, M. R., Römisch, J., Kerschbaumer, R. J., & Kreil, T. R. (2024). Immunoglobulin therapy in transition: Clinical needs, supply challenges, and solutions. Transfusion Medicine Reviews, 38(3), 150851.

Flan, B., & Arrabal, S. (2007). Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: Precautionary measures and efficacy of manufacturing processes in prion removal. Transfusion Clinique et Biologique, 14(1), 51–62.

Grazzini, G., Mannucci, P. M., & Oleari, F. (2013). Plasma-derived medicinal products: demand and clinical use. Blood Transfusion, 11(Suppl 4), s2–s5.

Ghasemi Z, Abolghasemi H, Babaei F, Cheraghali AM, Yousefi N. (2024) Plasma Production in Iran: Streaming Towards Plasma Self-sufficiency. Iran J Blood Cancer.16(1):59–66.

Hansen, M. (2017). Towards plasma self-sufficiency the process and the status in Denmark. Vox Sanguinis, 112, 7.

International Society of Blood Transfusion (ISBT). (2022). ISBT 2022 Abstract Book. ISBT Congress : Kuala Lumpur

Jacike, Z., Rajackaite, E., Sepetiene, R., Robbins, N., & Ali, M. (2024). Predictive Model of variable laboratory findings calculation and monitoring during plasmapheresis procedures. Annals of Blood, 9, 24

Kapsch, A.-M., Farcet, M. R., Wieser, A., Ahmad, M. Q., Miyabayashi, T., Baylis, S. A., Blümel, J., & Kreil, T. R. (2020). Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin. Transfusion, 60(10), 1–8.

Kementerian Kesehatan Republik Indonesia. (2023). Peraturan Menteri Kesehatan Nomor 4 Tahun 2023 tentang Penyelenggaraan Fraksionasi Plasma

Khan, H., Pervaiz, A., Intagliata, S., Das, N., Nagulapalli Venkata, K., Atanasov, A., Najda, A., Nabavi, S., Wang, D., Pittalà, V., & Bishayee, A. (2020). The analgesic potential of glycosides derived from medicinal plants. DARU, Journal of Pharmaceutical Sciences, 28(1), 387–401.

Knutson, F. (2017). Pathogen reduction – What are the advantages, what are the problems, what are the costs? Vox Sanguinis, 112(1), 5.

Lloyd, J., & Feldman, P. (2023). Preclinical development and characterization of a human plasma‐derived high‐purity factor X concentrate for therapeutic use. Haemophilia, 29(6), 1394–1409.

Leitner, G., Mitterer, A., & Reipert, B. (2022). The role of quality and infrastructure in plasma fractionation: A global perspective. Vox Sanguinis, 117(1), 97-134.

Montemurro, T., Lavazza, C., Montelatici, E., Budelli, S., La Rosa, S., Barilani, M., Mei, C., Manzini, P., Ratti, I., Cimoni, S., Brasca, M., Prati, D., Saporiti, G., Astori, G., Elice, F., Giordano, R., & Lazzari, L. (2024). Off-the-Shelf Cord-Blood Mesenchymal Stromal Cells: Production, Quality Control, and Clinical Use. Cells, 13(12), 1066.

Maryuningsih, Y. (2022). WHO Action Framework to advance universal access to safe, effective and quality assured blood products: how far are we? Vox Sanguinis, 117( 1), 20–21.

Parés, C., Martínez, M., Messeguer, J., & Rodríguez, E. (2015) Manufacturing of Plasma-Derived Medicinal Products: Qualification Process of Plasma Suppliers. PDA Journal of Pharmaceutical Science and Technology, 69(6), 620-630.

Putri, R. N., Syahrani, L., & Santosa, M. (2020). The use of intravenous immunoglobulin in systemic inflammatory conditions: A narrative overview. Book of Abstracts, Faculty of Medicine Annual Research Meeting 2020. Jakarta : Universitas Indonesia.

Sampieri L, Rodríguez-Lombardi G, Bernardi ME. (2024) In-house RT-PCR detection of hepatitis A virus in human plasma pools used for the manufacture of medicinal products. Transfusion and Apheresis Science. Vol 63:103869.

Schmidt, A. E., & Refaai, M. A. (2022). Blood derivative therapy. Annals of Blood, 7, 7.

Scaramuccia, D., & Farrugia, A. (2006). Securing commitment and control for the supply of plasma derivatives for public health systems. II: Managing demand and procurement. Biologicals, 34(1), 39–46.

Strengers, P. F., & Klein, H. G. (2016). Plasma is a strategic resource. Transfusion, 56(12), 3133–3137.

Squillaro, T., Peluso, G., & Galderisi, U. (2017). Clinical applications of mesenchymal stem

Triyono, T., & Bidayah, H. F. (2023) Plasma collection in Indonesia - a challenge to implement fractionation. Bali Medical Journal, 12(2), 1238-1242.

WHO. (2016) Essential medicines and health products [Internet]. Available from: http://www.who.int/medicines/publication/




DOI: https://doi.org/10.24198/farmaka.v22i3.64521

DOI (PDF): https://doi.org/10.24198/farmaka.v22i3.64521.g26099

Refbacks

  • Saat ini tidak ada refbacks.


##submission.license.cc.by-nc4.footer##

Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved